PBMs, PhRMA trade blame over drug costs in House hearing

Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

By Rebecca Pifer • Sept. 19, 2023

Novartis cancels Beigene partnership as cancer drug gains EU approval

The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

By Jonathan Gardner • Sept. 19, 2023

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

FTC takes aim at pharma patent tactics used to block generics

The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.

By Jonathan Gardner • Sept. 15, 2023

FDA approves updated COVID boosters from Pfizer, Moderna

Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.

By Delilah Alvarado • Sept. 11, 2023

Novartis stops work on gene therapy acquired in Gyroscope deal

The decision follows a review by a trial monitoring committee, which concluded data for the geographic atrophy treatment didn't support further development.

By Delilah Alvarado • Sept. 11, 2023

Manufacturing delays under-the-skin Tecentriq shot in US

Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.

By Jonathan Gardner • Sept. 8, 2023

Moderna says updated COVID shot likely to protect against worrisome variant

The findings add to early evidence showing a heavily mutated variant called BA.2.86, which is growing in prevalence, may not be as evasive as scientists once feared.

By Delilah Alvarado • Sept. 6, 2023

Roche claims study success for targeted drug in early lung cancer

The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.

By Ben Fidler • Sept. 1, 2023

Sanofi appoints a venture investor to R&D head as executive team expands

Houman Ashrafian, currently a scientific advisor at SV Health Investors, will fill the role left by John Reed, who oversaw the transformation of research and development during his five years at Sanofi.

By Jacob Bell • Aug. 31, 2023

The intelligent content ecosystem is here. Is your organization ready?

Is pharma up to the challenge of delivering the personalized and contextual experiences doctors have come to expect? Too often, the answer is no.

By Saby Mitra, Global Digital Customer Experience Practice Leader at ZS • Aug. 28, 2023

Roche’s surprise study results spur new optimism for TIGIT drugs

Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers. 

By Jonathan Gardner • Aug. 23, 2023

8 key components of a telemedicine program that delivers an exceptional patient experience

Discover how to accelerate patient access and commercial success through a best-in-class telemedicine program.

Aug. 21, 2023

Moderna builds case for updated COVID shot ahead of latest booster push

But the demand for booster shots ahead of an expected surge of infections this fall remains an unanswered question weighing heavily on Moderna’s future outlook. 

By Jonathan Gardner • Aug. 18, 2023

Merck says drug acquired in $1B buyout scores in large kidney cancer study

The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma. 

By Jacob Bell • Aug. 18, 2023

Boehringer moves Wegovy competitor into late-stage testing

The German pharmaceutical company is launching three Phase 3 trials of an obesity drug called survodutide, which like Wegovy targets the GLP-1 receptor

By Ned Pagliarulo • Aug. 17, 2023

Amazon Pharmacy expands insulin manufacturer coupons

The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.

By Rebecca Pifer • Aug. 17, 2023

Gilead antibody drug shows signs of potential in early lung cancer

A combination of Trodelvy and Merck’s Keytruda appears active against lung tumors, but has a high bar to clear and faces competition from AstraZeneca and Daiichi Sankyo.

By Jonathan Gardner • Aug. 17, 2023

A leading Democrat reveals how his mental health struggles shape his policy approach

Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.

By Karissa Waddick • Aug. 17, 2023

FDA approves bispecific drug from Pfizer for multiple myeloma

Elrexfio is the third bispecific antibody cleared to treat the cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

By Jonathan Gardner • Aug. 14, 2023

FDA delays decision on Valneva’s chikungunya vaccine

The agency needs more time to settle with Valneva the design of a post-marketing study for the shot, which could become the first preventive therapy for chikungunya available in the U.S.

By Delilah Alvarado • Aug. 14, 2023

The rise of the new pharma marketer in an evolving commercial model

Meet the pharma marketer of the future, primed for personalization and powered by technology.

Aug. 14, 2023

Novo hikes sales outlook on rising potential for obesity, diabetes drugs

The success of Wegovy in a landmark heart disease study has fueled higher sales projections, even though the Danish drugmaker is still struggling to maintain a big enough supply. 

By Jonathan Gardner • Aug. 10, 2023

J&J grows cancer drug portfolio with newly approved bispecific

The drug, which will be sold under the brand name Talvey, is now cleared by the FDA to treat multiple myeloma, a blood cancer that J&J has identified as a research priority.

By Jacob Bell • Aug. 10, 2023

Astellas to expand presence in Massachusetts with new research hub

The planned facility in the biotech hotspot of Cambridge will include incubator space for startups and adds to Astellas’ R&D footprint in the Boston area.

By Delilah Alvarado • Aug. 10, 2023

Novartis says drug helps control chronic hives in studies

The studies are another example of drugmakers exploring how so-called BTK inhibitors can be used to treat diseases outside of blood cancer. 

By Kristin Jensen • Aug. 9, 2023